In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on PharmaCyte Biotech (PMCB – Research Report). The company's shares closed last Wednesday at $2.15, close to its 52-week low of $1.79. According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.8% and a 23.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and TRACON Pharmaceuticals. PharmaCyte Biotech has an analyst consensus of Hold. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $16.90 and a one-year low of $1.79.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-hold-rating-for-pharmacyte-biotech-pmcb?utm_source=advfn.com&utm_medium=referral
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more PharmaCyte Biotech Charts.
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more PharmaCyte Biotech Charts.